COVID-19 vaccine development protocol: PSV Based Neutralization Assay Lentivirus (lente-, Latin for “slow”) is a genus of retroviruses, medium sized (80-100nm) and enveloped, slightly pleomorphic, spherical with an isometric nucleocapsid containing two copies of positive-sense ssRNA genome (Fig. 11A). Most lentiviral vectors are based on the Human Immunodeficiency Virus (HIV), which causes AIDS, a chronic […]
COVID-19 vaccine development protocol: PSV Based Neutralization Assay Adenovirus (AdV) vector-based vaccines Adenovirus (AdV) is a member of the family Adenoviridae, whose name derives from their initial isolation from human adenoids in 1953 [42]. It is a medium sized (90-100nm) and non-enveloped virus with an icosahedral nucleocapsid containing a 36kb double stranded DNA genome (Fig. […]
COVID-19 vaccine development protocol: PSV Based Neutralization Assay Viral vector-based vaccines Viral vector-based vaccines are vaccines that can deliver specific antigen gene to target cells based on the infection ability of viruses, produce antigens via the nutrition substances in host cells, and then provoke immune responses with the newly synthesized antigens. Compared with the traditional […]
COVID-19 vaccine development protocol: PSV Based Neutralization Assay Abstract The vaccine helps to provoke the immune system and is an efficacious means for disease prevention and treatment. At this particular time of the COVID-19 outbreak, the vaccine for COVID-19 is urgently needed to save tens of thousands of people’s lives. Here we give some basic […]
Variant of Concern 2021/03 Technical briefing 7 This briefing provides an update on previous briefings up to 13 February 2021 Summary • There are 4 variants of concern and 5 variants under investigation (Table 1) • A slightly increased risk of hospitalisation has been now been detected for VOC 202012/01 (B.1.1.7), supporting previous findings on […]
Variant of Concern 202012/01Technical briefing 6 This briefing provides an update on previous briefings up to 1 February 2021 Summary There are 4 variants of concern, designated: • VOC 202012/01 (B.1.1.7), first detected in Kent England is predominant in all regions and is circulating in multiple countries• VOC 202102/02 (B.1.1.7 cluster with E484K mutation), first detected in South West […]
Variant of Concern 202012/01Technical briefing 5 This briefing provides an update on the briefing of 14 January 2021 Summary SGTF detections indicate VOC202012/01 continues to predominate across all regions. S gene target failure remains a well correlated proxy measure of VOC 202012/01. An assessment of severity of disease has been conducted by NERVTAG. A limited […]
Variant of Concern 202012/01 Technical briefing 4 This briefing provides an update on the briefing of 8 January 2021 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, […]
The world is in midst of the COVID-19 pandemic.The SARS-CoV-2 lineage B.1.1.28 has been evolving in Brazil since February 2020. A new lineage, named P.1 (B.1.1.28.1), contains convergent mutations in the spike (S) protein, including several receptor binding domain (spike RBD) mutations E484K, K417T, and N501Y. Spike Mutation in SARS-COV-2 (2019nCOV) Brazilian variant P.1 lineage […]
Variant of Concern 202012/01Technical briefing 3 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following risk assessment with the relevant expert committee, they may […]
